Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021 – chatter @ #wallstreetbets

By
Mehabe
-
0
413

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021
https://www.businesswire.com/news/home/20210919005021/en/

RELATED ARTICLESMORE FROM AUTHOR

This site uses Akismet to reduce spam. Learn how your comment data is processed.